万基遗传(MYGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MYGN 万基遗传

交易中 07-16 15:30:35 EDT

6.13

-0.18

-2.85%

最高6.42	最低6.10	成交量60.44万
今开6.28	昨收6.31	日振幅5.07%
总市值5.79亿	流通市值4.83亿	总股本9,444万
成交额377.98万	换手率0.77%	流通股本7,878万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MYGN","market":"US","secType":"STK","nameCN":"万基遗传","latestPrice":6.13,"timestamp":1784230235123,"preClose":6.31,"halted":0,"volume":604395,"delay":0,"changeRate":-0.02852614896988902,"floatShares":78777800,"shares":94443029,"eps":-4.291923,"marketStatus":"交易中","change":-0.18,"latestTime":"07-16 15:30:35 EDT","open":6.28,"high":6.42,"low":6.1,"amount":3779830.5443415,"amplitude":0.050713,"askPrice":6.13,"askSize":543,"bidPrice":6.12,"bidSize":413,"shortable":3,"etf":0,"ttmEps":-4.291923,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784232000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":6.31,"preHourTrading":{"tag":"盘前","latestPrice":6.1001,"preClose":6.31,"latestTime":"09:10 EDT","volume":1565,"amount":9777.203849,"timestamp":1784207431165,"change":-0.2099,"changeRate":-0.033265,"amplitude":0.039604},"postHourTrading":{"tag":"盘后","latestPrice":6.32,"preClose":6.31,"latestTime":"19:54 EDT","volume":59880,"amount":377833.6465,"timestamp":1784159661352,"change":0.01,"changeRate":0.001585,"amplitude":0.001585},"volumeRatio":0.717954,"impliedVol":1.3352,"impliedVolPercentile":0.9363},"requestUrl":"/m/hq/s/MYGN","defaultTab":"news","newsList":[{"id":"1141791430","title":"新闻稿：万基遗传任命Raj Jampa为新任首席技术官","url":"https://stock-news.laohu8.com/highlight/detail?id=1141791430","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141791430?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:07","pubTimestamp":1780405633,"startTime":"0","endTime":"0","summary":"盐湖城，2026年6月2日——分子诊断与精准医疗领域的领导者万基遗传公司今日宣布，任命Raj Jampa担任公司首席技术官，该任命自2026年6月1日起生效。作为首席技术官，Jampa将负责制定和执行万基遗传技术组织的战略，包括进一步利用人工智能来提升运营效率和效能。万基遗传不承担任何义务，也明确声明不承担任何义务，以更新或修改任何前瞻性陈述，无论是由于新信息、未来事件或其他原因，法律要求的情况除外。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4160","CTO","LU1066051225.USD","LU1066051811.HKD","LU1066051498.USD","BK4139","MYGN","LU1066053197.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129201295","title":"万基遗传推出Prolaris® + AI，首款融合基因组学与数字病理人工智能的前列腺癌检测","url":"https://stock-news.laohu8.com/highlight/detail?id=1129201295","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129201295?lang=zh_cn&edition=full","pubTime":"2026-05-27 04:06","pubTimestamp":1779825975,"startTime":"0","endTime":"0","summary":"万基遗传推出了其首创的Prolaris® + AI前列腺癌检测产品。该检测首次将基因组学分析与数字病理学人工智能技术相结合。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197429393","title":"万基遗传Mychoice Cdx检测获FDA批准 成为卵巢癌药物Zejula伴随诊断方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1197429393","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197429393?lang=zh_cn&edition=full","pubTime":"2026-03-18 04:06","pubTimestamp":1773777976,"startTime":"0","endTime":"0","summary":"万基遗传（Myriad Genetics）宣布，其Mychoice Cdx检测正式获得美国食品药品监督管理局（FDA）批准，将作为Zejula（尼拉帕利）的伴随诊断工具，用于卵巢癌患者的治疗方案指导。这一批准标志着该检测在精准医疗领域应用的重要突破，将为临床医生提供更精准的用药依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616533961","title":"巨头入局！Myriad Genetics正式杀入MRD赛道，乳腺癌检测三月开售","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533961","media":"GLOIVD","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616533961?lang=zh_cn&edition=full","pubTime":"2026-03-04 08:00","pubTimestamp":1772582416,"startTime":"0","endTime":"0","summary":"2026年2月底，Myriad Genetics在发布其2025年第四季度及全年财报的同时，宣布了一个可能改变行业格局的决定：其名为“Precise”的MRD检测产品，将于3月初正式启动商业化销售，首发适应症为乳腺癌。新战役对于国内IVD从业者而言，Myriad Genetics是一个既熟悉又颇具分量的名字。肿瘤谱分析业务收入全年下降3%，药物基因组学业务更是因头部支付方UnitedHealthcare停止覆盖其GeneSight检测，而遭受重创，全年收入骤降15%。据披露，Precise MRD assay是一种“肿瘤知情”且基于“全基因组测序”的检测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603040812359542db8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603040812359542db8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MYGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616914533","title":"万基遗传盘中异动 下午盘急速拉升5.19%报5.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616914533","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616914533?lang=zh_cn&edition=full","pubTime":"2026-03-04 02:45","pubTimestamp":1772563533,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日02时45分，万基遗传股票出现波动，股价急速上涨5.19%。截至发稿，该股报5.27美元/股，成交量79.897万股，换手率0.85%，振幅9.78%。万基遗传股票所在的生命科学行业中，整体跌幅为0.71%。其相关个股中，Insight Molecular Diagnostics Inc.、Genedx Holdings Corp.、万基遗传涨幅较大，Xwell, Inc.、Ispecimen Inc.、Genedx Holdings Corp.较为活跃，换手率分别为33.19%、2.81%、2.00%，振幅较大的相关个股有Genedx Holdings Corp C/Wts 22/07/2026 、Xwell, Inc.、Genedx Holdings Corp.，振幅分别为32.85%、17.06%、16.36%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030402453397a7e44e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030402453397a7e44e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603026575","title":"万基遗传盘中异动 早盘急速拉升5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603026575","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603026575?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:33","pubTimestamp":1768228388,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时33分，万基遗传股票出现异动，股价大幅上涨5.78%。截至发稿，该股报6.96美元/股，成交量8.3208万股，换手率0.09%，振幅5.09%。万基遗传股票所在的生命科学行业中，整体涨幅为0.37%。其相关个股中，Biodesix, Inc.、万基遗传、Twist Bioscience Corporation涨幅较大，Biodesix, Inc.、Ispecimen Inc.、Genedx Holdings Corp.较为活跃，换手率分别为147.18%、0.37%、0.31%，振幅较大的相关个股有万基遗传、Exagen Inc.、纽勤，振幅分别为6.00%、4.89%、4.31%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222330997a175fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222330997a175fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518208004","title":"万基遗传盘中异动 大幅下挫5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208004","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518208004?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:41","pubTimestamp":1741624873,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日00时41分，万基遗传股票出现异动，股价快速下跌5.01%。截至发稿，该股报9.67美元/股，成交量34.2039万股，换手率0.37%，振幅5.89%。万基遗传股票所在的生命科学行业中，整体跌幅为0.24%。其相关个股中，Atlantic International Corp.、安奈特保险、恩佐生化涨幅较大，Ispecimen Inc.、安奈特保险、Mainz Biomed N.V.较为活跃，换手率分别为8.55%、4.52%、3.55%，振幅较大的相关个股有Xwell, Inc.、安奈特保险、Inotiv, Inc.，振幅分别为34.62%、27.57%、20.23%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311004113abf34170&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311004113abf34170&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517601768","title":"Piper Sandler：维持Myriad Genetics(MYGN.US)评级，由中性调整至中性评级, 目标价由14.00美元调整至11.50美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517601768","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517601768?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:02","pubTimestamp":1741107763,"startTime":"0","endTime":"0","summary":"Piper Sandler：维持Myriad Genetics(MYGN.US)评级，由中性调整至中性评级, 目标价由14.00美元调整至11.50美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05010248524009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516635066","title":"B of A Securities：维持Myriad Genetics(MYGN.US)评级，由低于大市调整至低于大市评级, 目标价由13.00美元调整至11.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635066","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516635066?lang=zh_cn&edition=full","pubTime":"2025-03-03 21:20","pubTimestamp":1741008035,"startTime":"0","endTime":"0","summary":"B of A Securities：维持Myriad Genetics(MYGN.US)评级，由低于大市调整至低于大市评级, 目标价由13.00美元调整至11.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03212048493049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516303875","title":"万基遗传盘中异动 股价大跌5.02%报10.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516303875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516303875?lang=zh_cn&edition=full","pubTime":"2025-03-01 02:58","pubTimestamp":1740769099,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日02时58分，万基遗传股票出现异动，股价大幅下挫5.02%。截至发稿，该股报10.51美元/股，成交量59.329万股，换手率0.65%，振幅6.42%。万基遗传股票所在的生命科学行业中，整体涨幅为0.19%。其相关个股中，Bioaffinity Technologies Inc C/Wts 07/09/2027 、Opko健康、Oncocyte Corporation涨幅较大，Ispecimen Inc.、Mainz Biomed N.V.、Prophase Labs, Inc.较为活跃，换手率分别为8.25%、6.54%、6.19%，振幅较大的相关个股有Bioaffinity Technologies Inc C/Wts 07/09/2027 、Genedx Holdings Corp C/Wts 22/07/2026 、Bioaffinity Technologies, Inc.，振幅分别为51.05%、23.17%、18.13%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301025819a2583f8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301025819a2583f8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MYGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516329379","title":"万基遗传2024财年实现净利润-1.27亿美元，同比增加51.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516329379","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516329379?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:00","pubTimestamp":1740758449,"startTime":"0","endTime":"0","summary":"3月1日，万基遗传公布财报，公告显示公司2024财年净利润为-1.27亿美元，同比增加51.71%；其中营业收入为8.38亿美元，同比增加11.29%，每股基本收益为-1.41美元。从资产负债表来看，万基遗传总负债3.27亿美元，其中短期债务12.80百万美元，资产负债比为3.15，流动比率为1.82。机构评级：截至2025年3月1日，当前有15家机构对万基遗传目标价做出预测，其中目标均价为17.33美元，其中最低目标价为8.00美元，最高目标价为29.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000108abe0ffb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000108abe0ffb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514012182","title":"雷蒙德詹姆斯公司：重申Myriad Genetics(MYGN.US)评级，由优于大市调整至优于大市评级, 目标价由27.00美元调整至19.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514012182","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514012182?lang=zh_cn&edition=full","pubTime":"2025-02-26 01:21","pubTimestamp":1740504092,"startTime":"0","endTime":"0","summary":"雷蒙德詹姆斯公司：重申Myriad Genetics(MYGN.US)评级，由优于大市调整至优于大市评级, 目标价由27.00美元调整至19.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26012148385987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514015414","title":"瑞银：维持Myriad Genetics(MYGN.US)评级，由中性调整至中性评级, 目标价由18.00美元调整至16.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514015414","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514015414?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:26","pubTimestamp":1740497169,"startTime":"0","endTime":"0","summary":"瑞银：维持Myriad Genetics(MYGN.US)评级，由中性调整至中性评级, 目标价由18.00美元调整至16.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25232648384059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514409002","title":"万基遗传股价重挫25.04% 市值跌2.36亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514409002","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514409002?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:31","pubTimestamp":1740493864,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分，万基遗传股票出现波动，股价大幅下跌25.04%。截至发稿，该股报10.33美元/股，成交量5.7055万股，换手率0.06%，振幅3.19%。最近的财报数据显示，该股实现营业收入2.13亿美元，净利润-22.10百万美元，每股收益-0.24美元，毛利1.39亿美元，市盈率-7.33倍。万基遗传股票所在的生命科学行业中，整体跌幅为0.26%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223104abdc7da5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223104abdc7da5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MYGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154128011","title":"异动解读 | 万基遗传盘后大跌7.69%，盘后季绩疲软导致股价下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=1154128011","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154128011?lang=zh_cn&edition=full","pubTime":"2025-02-25 05:36","pubTimestamp":1740432985,"startTime":"0","endTime":"0","summary":"万基遗传(NASDAQ:MYGN)今日盘后大跌7.69%，引发市场广泛关注。\n\n公司新一季度财报显示，其调整后每股收益为0.03美元，符合分析师预期。但营收为2.106亿美元，低于分析师预期的2.116亿美元，同比增长7.12%。\n\n营收小幅逊于预期或是导致万基遗传今日盘后股价大跌的主要原因。不过，该公司在近期核心业务表现依然强劲，新一季度收益增长对比同期仍有所增长，且符合预期。市场预计其股价短期内可能维持震荡，后市走势还需进一步观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145408278","title":"Myriad Genetics第四季度调整后每股收益$0.03，与预期一致，销售额$2.106亿低于预期$2.116亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1145408278","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145408278?lang=zh_cn&edition=full","pubTime":"2025-02-25 05:12","pubTimestamp":1740431567,"startTime":"0","endTime":"0","summary":"Myriad Genetics报告季度每股收益为$0.03，符合分析师的一致预期。这比去年同期的每股收益$0.04下降了25%。公司报告季度销售额为$2.106亿，低于分析师一致预期的$2.116亿，差距为0.48%。但相比去年同期的销售额$1.966亿增长了7.12%。以上内容来自Benzinga Earnings专栏，原文如下：Myriad Genetics  reported quarterly earnings of $0.03 per share which met the analyst consensus estimate. This is a 25 percent decrease over earnings of $0.04 per share from the same period last year.  The company reported quarterly sales of $210.60 million which missed the analyst consensus estimate of $211.62 million by 0.48 perc","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Myriad Genetics第四季度调整后每股收益$0.03，与预期一致，销售额$2.106亿低于预期$2.116亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513219511","title":"万基遗传盘中异动 下午盘快速下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513219511","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513219511?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:59","pubTimestamp":1740164370,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日02时59分，万基遗传股票出现异动，股价大幅下跌5.01%。截至发稿，该股报14.23美元/股，成交量42.4151万股，换手率0.47%，振幅6.28%。机构评级方面，在所有17家参与评级的机构中，41%的券商给予买入建议，35%的券商给予持有建议，24%的券商给予卖出建议。万基遗传股票所在的生命科学行业中，整体跌幅为0.53%。万基遗传公司简介：Myriad Genetics Inc是一家分子诊断公司，提供旨在评估个人患病风险的检测服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222025930962bb529&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222025930962bb529&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MYGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512483648","title":"万基遗传盘中异动 急速拉升5.08%报15.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512483648","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512483648?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:43","pubTimestamp":1739976228,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时43分，万基遗传股票出现波动，股价快速上涨5.08%。截至发稿，该股报15.31美元/股，成交量19.863万股，换手率0.22%，振幅5.63%。万基遗传股票所在的生命科学行业中，整体涨幅为0.39%。其相关个股中，Prophase Labs, Inc.、Prenetics Global Limited C/Wts 18/05/2027 、恩佐生化涨幅较大，Prophase Labs, Inc.、Ispecimen Inc.、Mainz Biomed N.V.较为活跃，换手率分别为28.43%、1.89%、1.64%，振幅较大的相关个股有Prophase Labs, Inc.、Genedx Holdings Corp C/Wts 22/07/2026 、Grail, Inc.，振幅分别为18.00%、12.36%、8.91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219224348a24bfc38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219224348a24bfc38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MYGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511452439","title":"万基遗传盘中异动 早盘股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511452439","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511452439?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:29","pubTimestamp":1739460567,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时29分，万基遗传股票出现波动，股价大幅上涨5.04%。截至发稿，该股报13.75美元/股，成交量14.4088万股，换手率0.16%，振幅5.04%。机构评级方面，在所有17家参与评级的机构中，41%的券商给予买入建议，35%的券商给予持有建议，24%的券商给予卖出建议。万基遗传股票所在的生命科学行业中，整体跌幅为0.06%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232928abcdbd42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232928abcdbd42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MYGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509234483","title":"万基遗传盘中异动 股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509234483","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509234483?lang=zh_cn&edition=full","pubTime":"2025-02-06 01:39","pubTimestamp":1738777171,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日01时39分，万基遗传股票出现波动，股价快速上涨5.08%。截至发稿，该股报13.04美元/股，成交量50.4693万股，换手率0.55%，振幅5.40%。机构评级方面，在所有16家参与评级的机构中，38%的券商给予买入建议，38%的券商给予持有建议，24%的券商给予卖出建议。万基遗传股票所在的生命科学行业中，整体跌幅为0.02%。万基遗传公司简介：Myriad Genetics Inc是一家分子诊断公司，提供旨在评估个人患病风险的检测服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206013931a23aa41b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206013931a23aa41b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MYGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.myriad.com","stockEarnings":[{"period":"1week","weight":0.075},{"period":"1month","weight":0.4606},{"period":"3month","weight":0.262},{"period":"6month","weight":0.0659},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.026}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0},{"period":"3month","weight":0.0757},{"period":"6month","weight":0.0913},{"period":"1year","weight":0.2132},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Myriad Genetics, Inc.于1992年11月6日根据特拉华州法律注册成立。该公司是一家领先的基因检测和精准医疗公司，致力于促进所有人的健康和福祉。该公司提供的洞察力帮助人们控制自己的健康，并使医疗保健提供者能够更好地发现、治疗和预防疾病。该公司开发并提供测试，帮助评估疾病或疾病进展的风险，并指导跨医学专业的治疗决策，在这些专业中，基因洞察力可以显著改善患者护理并降低医疗成本。","yearOnYearQuotes":[{"month":1,"riseRate":0.548387,"avgChangeRate":0.064948},{"month":2,"riseRate":0.258065,"avgChangeRate":-0.012645},{"month":3,"riseRate":0.483871,"avgChangeRate":0.015641},{"month":4,"riseRate":0.451613,"avgChangeRate":-0.001268},{"month":5,"riseRate":0.516129,"avgChangeRate":0.003025},{"month":6,"riseRate":0.451613,"avgChangeRate":0.020363},{"month":7,"riseRate":0.548387,"avgChangeRate":0.015629},{"month":8,"riseRate":0.633333,"avgChangeRate":0.015846},{"month":9,"riseRate":0.5,"avgChangeRate":0.04385},{"month":10,"riseRate":0.566667,"avgChangeRate":0.044634},{"month":11,"riseRate":0.516129,"avgChangeRate":0.02599},{"month":12,"riseRate":0.483871,"avgChangeRate":-0.004191}],"exchange":"NASDAQ","name":"万基遗传","nameEN":"Myriad Genetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万基遗传(MYGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万基遗传(MYGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万基遗传,MYGN,万基遗传股票,万基遗传股票老虎,万基遗传股票老虎国际,万基遗传行情,万基遗传股票行情,万基遗传股价,万基遗传股市,万基遗传股票价格,万基遗传股票交易,万基遗传股票购买,万基遗传股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万基遗传(MYGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万基遗传(MYGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}